Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big Pharma partner with deep pockets — and with it, a new name and facelift.

Regeneron is betting nearly $1 billion on five...

Click to view original post